OCGN - Ocugen to Host Clinical Showcase in New York City on Wednesday February 21 2024 | Benzinga
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024
Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host an in-person Clinical Showcase on Wednesday, February 21, 2024. The event will take place from 10 a.m.-noon ET at the Nasdaq Market Site in Times Square, New York City.
The Clinical Showcase will provide an opportunity to learn more about the upcoming Phase 3 trial of OCU400—including more specifics on study design and the broad indication for the treatment of retinitis pigmentosa, as well as a clinical study update from the ongoing Phase 1/2 trial of OCU400. A panel discussion will offer background on the genesis of modifier gene therapy and how this potential first-in-class treatment approach has evolved from the lab into the clinic.
Ocugen presenters include:
- Dr. Shankar Musunuri, Chairman, CEO & Co-founder
- Mike Shine, SVP ...